SCHEMBL4893357

SCHEMBL4893357

Cc1ccc(N)cc1Nc1nccc(-c2ccc(-n3ccnc3)cc2)n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 8/20 0.61
BCR P11274 7/20 0.61
IKBKB O14920 1/20 0.54
LCK P06239 1/20 0.48
PRKCA P17252 3/20 0.48
PDGFRB P09619 3/20 0.48
PDGFRA P16234 3/20 0.48
SRC P12931 2/20 0.48
PRKCD Q05655 1/20 0.48
CAMKK2 Q96RR4 1/20 0.47
LMNA P02545 1/20 0.45
MAPT P10636 1/20 0.45
ACVR1 Q04771 1/20 0.44
PIK3CG P48736 1/20 0.43
PSEN1 P49768 1/20 0.42
PSEN2 P49810 1/20 0.42
APH1B Q8WW43 1/20 0.42
NCSTN Q92542 1/20 0.42
APH1A Q96BI3 1/20 0.42
PSENEN Q9NZ42 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4893348 0.85 CAMKK2 (0.62) ABL1BCRIKBKBLCKPRKCA
SCHEMBL4903199 0.83 IKBKB (0.64) ABL1BCRIKBKBPRKCAPDGFRB
SCHEMBL4903439 0.83 IKBKB (0.50) ABL1BCRIKBKBPRKCAPDGFRB
SCHEMBL2580846 0.82 ABL1 (0.74) ABL1BCRLCKPRKCAPDGFRB
SCHEMBL4902208 0.81 ABL1 (0.67) ABL1BCRIKBKBPRKCAPDGFRB
SCHEMBL7601457 0.80 ABL1 (0.78) ABL1BCRLCKPRKCAPDGFRB
SCHEMBL4901347 0.80 PDGFRA (0.69) ABL1BCRLCKPRKCAPDGFRB
SCHEMBL14088811 0.79 IKBKB (0.48) ABL1BCRIKBKBPRKCAPDGFRB
Hydrochloric Acid SCHEMBL5205211 0.79 ABL1 (0.76) ABL1BCRLCKPRKCAPDGFRB
SCHEMBL4900996 0.78 PDGFRA (0.70) ABL1BCRLCKPRKCAPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080187575-A1 Pyrimidine Derivatives VICHEM CHEMIE KFT (HU) 2008-08-07 US claimed
EP-1786781-A2 PYRIMIDINE DERIVATIVES GPC Biotech AG (DE) 2007-05-23 EP claimed
WO-2006021458-A2 PYRIMIDINE DERIVATIVES GPC BIOTECH AG (DE) 2006-03-02 WO claimed
US-20080187575-A1 Pyrimidine Derivatives VICHEM CHEMIE KFT (HU) 2008-08-07 US disclosed
US-20080187575-A1 Pyrimidine Derivatives VICHEM CHEMIE KFT (HU) 2008-08-07 US disclosed
US-20080187575-A1 Pyrimidine Derivatives VICHEM CHEMIE KFT (HU) 2008-08-07 US disclosed
EP-1786781-A2 PYRIMIDINE DERIVATIVES GPC Biotech AG (DE) 2007-05-23 EP disclosed
WO-2006021458-A2 PYRIMIDINE DERIVATIVES GPC BIOTECH AG (DE) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080187575-A1 Pyrimidine Derivatives TYMP, TDP1, PNP ABL1 2843/4885BCR 2315/4885IKBKB 875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.